Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Karyopharm Therapeutics Inc. (KPTI)

Karyopharm files Chapter 11; existing common stock to be cancelled with no distribution

Negative Impact 5 of 5 restructuring Written later

Karyopharm Therapeutics and its subsidiary KPT Texas LLC filed voluntary Chapter 11 petitions on November 2, 2026, in the U.S. Bankruptcy Court for the Southern District of Texas, after a restructuring support agreement with lenders, noteholders and others. Under the proposed prepackaged plan, the company's existing common stock and Series A Convertible Preferred Stock would be cancelled, and holders would receive no distribution on those shares.

Key points

  • Petition Date was November 2, 2026; the company will operate as a debtor-in-possession under Court supervision.
  • Ayrmid Ltd. is the stalking horse bidder for a merger with the reorganized company, with bid protections of a 3% break-up fee and expense reimbursement capped at 1% of the Bid Protection Base.
  • Voting deadline on the prepackaged plan is November 30, 2026; the requested confirmation hearing is on or about January 11, 2027, subject to Court availability.
  • The Ayrmid term sheet contemplates a new senior secured term loan of up to $135 million, with up to $50 million of New Money DIP Loans to be repaid from its proceeds.

The filing

CompanyKaryopharm Therapeutics Inc. (KPTI)
Form8-K, current report
Filed with the SECNov 2, 2026, 9:58 PM ET
Accession number0001193125-26-444164

Items reported: 1.01 Material Definitive Agreement1.03 Bankruptcy or Receivership2.03 New Direct Financial Obligation2.04 Obligation Accelerated7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.